Aarey Drugs (AAREYDRUGS) | Financial Analysis & Statements
Aarey Drugs & Pharmaceuticals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.0B
Gross Profit
43.7M
4.28%
Operating Income
12.2M
1.19%
Net Income
13.7M
1.34%
EPS (Diluted)
₹0.48
Balance Sheet Metrics
Total Assets
2.9B
Total Liabilities
1.5B
Shareholders Equity
1.4B
Debt to Equity
1.10
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Aarey Drugs Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.7B | 4.0B | 4.1B | 4.9B | 3.5B |
| Cost of Goods Sold | 4.6B | 3.8B | 4.0B | 4.7B | 3.4B |
| Gross Profit | 101.7M | 132.0M | 90.1M | 195.5M | 101.0M |
| Gross Margin % | 2.2% | 3.3% | 2.2% | 4.0% | 2.9% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 11.2M | 5.9M | 7.0M | 10.0M | 4.8M |
| Other Operating Expenses | 49.6M | 68.4M | 33.8M | 54.2M | 39.1M |
| Total Operating Expenses | 60.8M | 74.3M | 40.8M | 64.2M | 43.9M |
| Operating Income | 8.1M | 28.2M | 20.0M | 94.9M | 37.2M |
| Operating Margin % | 0.2% | 0.7% | 0.5% | 1.9% | 1.1% |
| Non-Operating Items | |||||
| Interest Income | 56.0M | 48.7M | 26.3M | 20.1M | 24.3M |
| Interest Expense | 38.8M | 43.1M | 26.1M | 19.1M | 23.2M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 61.0M | 53.4M | 60.1M | 100.4M | 83.0M |
| Income Tax | 20.8M | 6.6M | 22.4M | 34.8M | 17.9M |
| Effective Tax Rate % | 34.1% | 12.3% | 37.3% | 34.7% | 21.5% |
| Net Income | 40.2M | 46.8M | 37.7M | 65.5M | 65.1M |
| Net Margin % | 0.9% | 1.2% | 0.9% | 1.3% | 1.9% |
| Key Metrics | |||||
| EBITDA | 119.3M | 113.7M | 102.4M | 139.8M | 115.4M |
| EPS (Basic) | ₹1.42 | ₹1.84 | ₹1.49 | ₹2.72 | ₹2.79 |
| EPS (Diluted) | ₹1.42 | ₹1.84 | ₹1.49 | ₹2.72 | ₹2.79 |
| Basic Shares Outstanding | 28254000 | 25414000 | 25385000 | 24075000 | 23384684 |
| Diluted Shares Outstanding | 28254000 | 25414000 | 25385000 | 24075000 | 23384684 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Aarey Drugs Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 14.7M | 15.9M | 7.1M | 1.9M | 6.5M |
| Short-term Investments | 17.6M | 13.0M | 4.2M | 75.1M | 129.9K |
| Accounts Receivable | 1.3B | 1.8B | 1.9B | 1.4B | 1.6B |
| Inventory | 454.9M | 346.8M | 288.2M | 136.8M | 184.6M |
| Other Current Assets | 644.0K | 644.0K | 644.0K | 14.6M | 264.0K |
| Total Current Assets | 2.7B | 2.8B | 2.7B | 2.2B | 2.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 2.0M | 2.0M | 2.0M | 1.8M | 1.4M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 243.3M | 207.1M | 207.2M | 263.5M | 146.6M |
| Total Assets | 2.9B | 3.0B | 2.9B | 2.5B | 2.3B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.0B | 1.3B | 1.3B | 1.1B | 1.1B |
| Short-term Debt | 328.7M | 281.3M | 333.6M | 108.2M | 180.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 86.9M | 54.1M | 21.7M | 10.2M | -2 |
| Total Current Liabilities | 1.5B | 1.7B | 1.7B | 1.3B | 1.3B |
| Non-Current Liabilities | |||||
| Long-term Debt | 19.9M | 32.2M | 43.6M | 33.4M | 0 |
| Deferred Tax Liabilities | 9.2M | 7.5M | 14.2M | 14.6M | 33.7M |
| Other Non-Current Liabilities | -1.0K | 178.0K | -1.0K | -1.0K | 20.0K |
| Total Non-Current Liabilities | 29.1M | 39.9M | 57.8M | 48.0M | 33.7M |
| Total Liabilities | 1.5B | 1.7B | 1.7B | 1.3B | 1.3B |
| Equity | |||||
| Common Stock | 284.5M | 280.5M | 253.8M | 253.8M | 233.8M |
| Retained Earnings | 571.3M | 531.1M | 484.2M | 446.5M | 381.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.4B | 1.3B | 1.2B | 1.1B | 988.6M |
| Key Metrics | |||||
| Total Debt | 348.6M | 313.5M | 377.2M | 141.6M | 180.2M |
| Working Capital | 1.2B | 1.2B | 1.0B | 920.8M | 875.7M |
Balance Sheet Composition
Aarey Drugs Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 61.0M | 53.4M | 60.1M | 100.3M | 83.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | 0 | 0 |
| Working Capital Changes | 258.4M | -130.9M | -271.7M | -110.0M | -379.2M |
| Operating Cash Flow | 366.1M | -33.7M | -182.9M | 10.2M | -271.8M |
| Investing Activities | |||||
| Capital Expenditures | -52.0M | -7.2M | -10.4M | -22.0M | -28.8M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -7.4M | -9.8M | -4.2M | -23.9M | - |
| Investment Sales | 0 | 0 | 19.0M | 0 | - |
| Investing Cash Flow | -59.4M | -17.0M | 4.4M | -32.1M | -28.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 731.0K | 42.2M | 0 | - |
| Debt Repayment | -15.1M | -11.4M | 0 | -39.8M | - |
| Financing Cash Flow | 1.8M | 99.6M | 42.2M | 42.5M | 0 |
| Free Cash Flow | 51.0M | -37.2M | -23.3M | -17.0M | 26.0M |
| Net Change in Cash | 308.5M | 48.9M | -136.3M | 20.7M | -300.6M |
Cash Flow Trend
Aarey Drugs Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
72.40
Price to Book
1.66
Price to Sales
0.64
PEG Ratio
-3.14
Profitability Ratios
Profit Margin
0.88%
Operating Margin
-2.43%
Return on Equity
2.91%
Return on Assets
1.39%
Financial Health
Current Ratio
1.79
Debt to Equity
38.27
Beta
0.80
Per Share Data
EPS (TTM)
₹1.22
Book Value per Share
₹53.06
Revenue per Share
₹136.90
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AAREYDRUGS | 2.5B | 72.40 | 1.66 | 2.91% | 0.88% | 38.27 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





